Arcutis Biotherapeutics Q4 GAAP EPS $(0.72) Beats $(0.78) Estimate, Sales $13.53M Beat $11.34M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics (NASDAQ:ARQT) reported Q4 GAAP EPS of $(0.72), surpassing the $(0.78) estimate, and sales of $13.53M, exceeding the $11.34M estimate. This represents a 38.98% improvement in EPS and a 356.81% increase in sales year-over-year.
February 27, 2024 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcutis Biotherapeutics reported better-than-expected Q4 earnings and sales, showing significant improvement over the previous year.
Arcutis Biotherapeutics' Q4 earnings and sales not only surpassed analyst expectations but also showed substantial improvement compared to the same period last year. This positive performance, especially in terms of sales growth, could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100